

RADIOPHARMACEUTICALS





Radiopharmaceuticals

Jubilant Pharma Ltd, a wholly-owned subsidiary of Jubilant Life Sciences and through its sub-business unit, Jubilant DraxImage Inc (JDI), is focused strictly on the field of Nuclear Medicine. Nuclear Medicine is a medical specialty that uses radioactive tracers (radiopharmaceuticals) to diagnose, treat and monitor disease.

JDI is a world-class nuclear medicine company, headquartered in Montreal, Canada, with a solid foundation in specialty Pharma that develops, manufactures and commercializes radiopharmaceuticals used for the diagnosis and treatment of various diseases. The company has **over 170 highly skilled employees** dedicated to providing high quality and reliable products and services to health care providers around the world for more than 60 years.

The company, a market leader in North America, is well positioned for long term growth. In addition to a diverse portfolio of US Food and Drug Administration (FDA) and Health Canada approved products, JDI has a comprehensive product pipeline that secures its position as global leaders by 2023. JDI continues to invest heavily in R&D to bring new innovative radiopharmaceuticals and enabling technologies to the market, to expand the clinical utility of nuclear medicine, ultimately enabling the early and accurate diagnosis of diseases and providing better patient outcomes.

JDI has strong partnerships and ongoing collaborations with the National Institute of Health (NIH), numerous medical societies, regulatory agencies, institutions and key opinion leaders across the globe in pursuit of its vision to Improve Lives Through Nuclear Medicine.

JDI's corporate values focus on cultivating world-class talent committed to quality and innovation, with a promise of providing the highest quality radiopharmaceuticals and advanced technologies, products and solutions to healthcare professionals so they can provide the highest quality care to their patients.

The **FDA, Health Canada, International Organization for Standardization (ISO), Canadian Nuclear Safety Commission (CNSC) and Nuclear Regulatory Commission (NRC)** regulate and certify the Company's highly specialized manufacturing facility from a pharmaceutical, radioactive and device perspective.

JDI's broad portfolio of products includes **diagnostic and therapeutic agents, as well as state-of-the-art devices, for cardiology, oncology, pulmonology, and endocrinology**. JDI products are supplied to national commercial radiopharmacy networks, regional health systems, stand-alone imaging centers, and hospitals worldwide. The bedrock of the business are its lyophilized "cold kits", radioactive "hot products" and more recently a cutting edge cardiac PET tracer (Rb-82).

JDI continues to increase the range of product offerings in **North America, while expanding into the Latin America, European and Asian markets** through collaboration, contractual arrangements with partners and new distribution channels to drive growth in current and future products.

PRODUCT OFFERINGS

Jubilant DraxImage Distribution Countries

(Approved & Marketed Products – Current Listing as on September 1, 2018)

USA

Drax Exametazime™
DRAXIMAGE® MAA
DRAXIMAGE® DTPA
DRAXIMAGE® I-131 Diagnostic Capsules
HICON® Sodium Iodine I 131 Solution USP
DRAXIMAGE® MDP-25
DRAXIMAGE® Sestamibi
SMART-FILL® Dispensing System
RUBY-FILL® (Rubidium Rb82 Generator & RUBY Rubidium Elution System)

CANADA

RUBY-FILL® (Rubidium Rb82 Generator)
RUBY Rubidium Elution System Device
DRAXIMAGE® MDP-25
DRAXIMAGE® MAA
DRAXIMAGE® DTPA
DRAXIMAGE® I-131 Diagnostic Capsules
DRAXIMAGE® I-131 Diagnostic Solution
DRAXIMAGE® I-131 Therapeutic Capsule
DRAXIMAGE® I-131 Therapeutic Solution
DRAXIMAGE® MDP-10
DRAXIMAGE® Sestamibi
DRAXIMAGE® Glucoptate
HICON® Sodium Iodine I 131 Solution USP

EUROPE

United Kingdom

DRAXIMAGE® Sestamibi (DRAXMIBI)
DRAXIMAGE® MDP-10

Netherlands

DRAXIMAGE® MDP-10
DRAXIMAGE® Sestamibi

Switzerland

RUBY-FILL® (Rubidium Rb82 Generator)

Luxembourg

RUBY-FILL® (Rubidium Rb82 Generator)

Germany

RUBY-FILL® (Rubidium Rb82 Generator)

ROW

Columbia

DRAXIMAGE® Sestamibi (pending)
DRAXIMAGE® MDP-10
HICON® Sodium Iodine I 131 Solution USP

Bermuda

DRAXIMAGE® I-131 Therapeutic Capsule
DRAXIMAGE® DTPA
DRAXIMAGE® MAA

Barbados

DRAXIMAGE® DTPA

Jamaica

DRAXIMAGE® DTPA
DRAXIMAGE® Sestamibi
DRAXIMAGE® Glucoptate
DRAXIMAGE® MDP-10
DRAXIMAGE® I-131 Therapeutic Solution

Trinidad & Tobago

DRAXIMAGE® I-131 Therapeutic Solution
DRAXIMAGE® I-131 Therapeutic Capsule
DRAXIMAGE® MDP-10

Venezuela

HICON® Sodium Iodine I 131 Solution USP

Cayman Islands

DRAXIMAGE® I-131 Diagnostic Solution
DRAXIMAGE® MAA

Costa Rica

DRAXIMAGE® I-131 Therapeutic Solution
DRAXIMAGE® I-131 Therapeutic Capsule

New Zealand

DRAXIMAGE® MDP-10
DRAXIMAGE® MAA
DRAXIMAGE® DTPA

Israel

DRAXIMAGE® MDP-10

DRAXIMAGE® MAA

DRAXIMAGE® DTPA

Philippines

DRAXIMAGE® MDP-10

DRAXIMAGE® MAA

DRAXIMAGE® DTPA

KSA

DRAXIMAGE® MDP-10

DRAXIMAGE® DTPA

DRAXIMAGE® Sestamibi

DRAXIMAGE® Gluceptate

India

DRAXIMAGE® Sestamibi

State of the Art Facility

3 Hot Cells

1 Isolator

1 Automated Loading Station

4 Semi-Automated Loading Stations

Packaging Station

Regulatory and Quality Approvals:

ISO 13485:2016

ISO CE Mark Certified

Health Canada

US-FDA

CNSC (Canadian Nuclear Safety Commission)

NRC (US Nuclear Regulatory Commission)

Product Portfolio For Your Diagnostic & Therapeutic Needs

Brain Imaging

- DTPA and Gluceptate

Cardiac PET Imaging

- RUBY-FILL®

Kidney Imaging

- DTPA and Gluceptate

Bone Imaging

- MDP

Thyroid Therapy

- I-131 Iodine and HICON®

Cardiac SPECT Imaging

- Sestamibi

Functional Lung Imaging

- MAA and DTPA

Leukocyte Labeling

- Exametazime



Jubilant DraxImage, Inc.

16751, Trans-Canada Highway,
Kirkland (Montreal), Québec, Canada H9H 4J4
Tel : 1-800-361-2356 or +514-694-8220

Our offices are open Monday to Friday from 8:00 AM to 5:00 PM Eastern Time

For business inquiries e-mail: customerservice@jdi.jubl.com
www.draximage.com

